Possible acute rejection associated with the use of the new antihepatitis C virus medications
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Avicenna Journal of Medicine |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/AJM.AJM_171_17 |
id |
doaj-f31e5abbef6b427fbb755c5d33f5dd8e |
---|---|
record_format |
Article |
spelling |
doaj-f31e5abbef6b427fbb755c5d33f5dd8e2021-08-10T00:06:29ZengWolters Kluwer Medknow PublicationsAvicenna Journal of Medicine2231-07702249-44642019-01-01901323410.4103/AJM.AJM_171_17Possible acute rejection associated with the use of the new antihepatitis C virus medicationsKhaled Ar Karkout0Saleema Al Sherif1Qutaiba Hussein2Alia Albawardi3Yousef Boobes4Department of Internal Medicine, Tawam Hospital, AlAin, United Arab EmiratesDepartment of Internal Medicine, Tawam Hospital, AlAin, United Arab EmiratesDivision of Nephrology, Tawam Hospital, AlAin, United Arab EmiratesDepartment of Pathology, College of Medicine and Health Sciences, UAE University, AlAin, United Arab EmiratesDivision of Nephrology, Tawam Hospital, AlAin, United Arab EmiratesHepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donorspecific antibodies. This report is aimed to increase awareness about the urgent need for further studies.http://www.thieme-connect.de/DOI/DOI?10.4103/AJM.AJM_171_17acute rejectionanti-hepatitis c virus medicationdaclatasvirdirect-acting antiviral agentskidney transplantsofosbuvir |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Khaled Ar Karkout Saleema Al Sherif Qutaiba Hussein Alia Albawardi Yousef Boobes |
spellingShingle |
Khaled Ar Karkout Saleema Al Sherif Qutaiba Hussein Alia Albawardi Yousef Boobes Possible acute rejection associated with the use of the new antihepatitis C virus medications Avicenna Journal of Medicine acute rejection anti-hepatitis c virus medication daclatasvir direct-acting antiviral agents kidney transplant sofosbuvir |
author_facet |
Khaled Ar Karkout Saleema Al Sherif Qutaiba Hussein Alia Albawardi Yousef Boobes |
author_sort |
Khaled Ar Karkout |
title |
Possible acute rejection associated with the use of the new antihepatitis C virus medications |
title_short |
Possible acute rejection associated with the use of the new antihepatitis C virus medications |
title_full |
Possible acute rejection associated with the use of the new antihepatitis C virus medications |
title_fullStr |
Possible acute rejection associated with the use of the new antihepatitis C virus medications |
title_full_unstemmed |
Possible acute rejection associated with the use of the new antihepatitis C virus medications |
title_sort |
possible acute rejection associated with the use of the new antihepatitis c virus medications |
publisher |
Wolters Kluwer Medknow Publications |
series |
Avicenna Journal of Medicine |
issn |
2231-0770 2249-4464 |
publishDate |
2019-01-01 |
description |
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donorspecific antibodies. This report is aimed to increase awareness about the urgent need for further studies. |
topic |
acute rejection anti-hepatitis c virus medication daclatasvir direct-acting antiviral agents kidney transplant sofosbuvir |
url |
http://www.thieme-connect.de/DOI/DOI?10.4103/AJM.AJM_171_17 |
work_keys_str_mv |
AT khaledarkarkout possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT saleemaalsherif possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT qutaibahussein possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT aliaalbawardi possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT yousefboobes possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications |
_version_ |
1721213156001316864 |